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Available online 10 May 2016Immune activation in HIV-1-infected individuals is reduced under antiretroviral therapies, but persists, resulting
in various morbidities. To better characterize this phenomenon, using a panel of 68 soluble and cell surface
markers, we measured the level of activation in circulating CD4+ and CD8+ T cells, B cells, monocytes, NK
cells, polynuclear and endothelial cells as well as of inﬂammation and ﬁbrinolysis in 120 virologic responders
over 45 years of age. As comparedwith age- and sex-matched uninfected individuals, we observed a persistence
of activation in all the cell subpopulations analyzed, together with marks of inﬂammation and ﬁbrinolysis. Two
independent hierarchical clustering analyses allowed us to identify ﬁve clusters of markers that varied concur-
rently, and ﬁve patient groups, each with the same activation proﬁle. The ﬁve groups of patients could be char-
acterized by a marker of CD4+ T cell, CD8+ T cell, NK cell, monocyte activation or of inﬂammation,
respectively. One of these proﬁles was strongly associated with marks of metabolic syndrome, particularly
with hyperinsulinemia (OR 12.17 [95% CI 1.79–82.86], p= 0.011). In conclusion, our study unveils biomarkers
linked to metabolic syndrome that could be tested as predictive markers, and opens the way to new therapeutic
approaches tailored to each patient group.
© 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Endothelium1. Introduction
Today, about 90% of treated persons living with HIV are aviremic
(Delaugerre et al., 2015). Yet, 6 to 24% of these virologic responders
do not restore their CD4 count as they should, exposing them to the
risk of immune deﬁciency-linked morbidities (Corbeau and Reynes,
2011). Themain reason for that is the persistence of a state of hyperactiv-
ity of the immune system in these patients (Corbeau and Reynes, 2011).s, CNRS UPR1142, 141 rue de la
en access article under the CC BY-NCThis residual immune activation also fuels the so-called non-AIDS-linked
morbidities such as atherothrombosis, osteoporosis,metabolic syndrome,
neurocognitive disorders, liver steatosis, kidney failure, frailty, and some
types of cancer (Hunt, 2012). These comorbidities are now the major
cause of morbi-mortality in treated patients (Lau et al., 2007).
HIV infection is characterized by the high level of immune activation
induced in the human organism. Various causes may combine to pro-
voke this immune hyperactivity (Younas et al., 2015). A ﬁrst cause is
the presence of the virus itself, detected by the immune system as a
xenoantigen and a danger. For example, gp120 has recently been
shown to activate monocytes and macrophages via TLR4 (Del Corno et
al., 2016). A second cause is the infection process that triggers a DNAde-
tection system resulting in inﬂammatory cytokine production (Doitsh-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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barrier that opens the way for intestinal microbes to enter the human
organism (Zevin et al., 2016). A fourth cause is the microbes that co-in-
fect the organism (Boulougoura and Sereti, 2016), as for instance hepa-
titis (Kovacs et al., 2008) or herpes viruses (Sheth et al., 2008). Aﬁfth set
of causes is linked to some effects of HIV on the immune system itself:
CD4+ T lymphopenia (Zonios et al., 2008; Sereti et al., 2009),
immunosenescence (Effros et al., 2003) and an imbalance in the
CD4+ T cell subpopulations (Kanwar et al., 2010). Finally, metabolic
dysregulation may also be a source of immune activation (Aounallah
et al., 2016; Dagenais-Lussier et al., 2015; Palmer et al., 2016). For in-
stance, lipid peroxidation may fuel monocyte activation (Zidar et al.,
2015). Moreover, the oxidative stress in the course of HIV infection
might increase inﬂammatory cytokines production (Chaudhri and
Clark, 1989). Combined antiretroviral therapies (cART) reduce all the
sources of immune activation without abolishing them (Palmer et al.,
2008; Guadalupe et al., 2003; Gonzalez et al., 2009; Stone et al., 2005).
Consequently, immune activation is only partly downregulated in
aviremic patients under treatment.
Previous works have shed a partial light on this phenomenon. The
adaptative and the innate immune systems, including inﬂammation,
are both involved. T cell activation has been particularly studied. Many
authors have shown the persistence of marks of CD4+ and CD8+ T
cell activation (Hunt et al., 2003), exhaustion (Cockerham et al.,
2014), and senescence (Stone et al., 2005) under cART. The same is
true for NK cells (Lichtfuss et al., 2012; Mavilio et al., 2005). Likewise,
B cells remain unquiet in virologic responders, as testiﬁed by the pres-
ence of hyperglobulinemia (De Milito et al., 2004). In the same type of
patients, high peripheral blood levels of soluble CD14 (sCD14) and sol-
uble CD163 (sCD163) have also been reported (Lichtfuss et al., 2012;
Burdo et al., 2011; Rajasuriar et al., 2010; Wallet et al., 2010; Kamat et
al., 2012), considered as signs of monocyte/macrophage hyperactivity.
Even neutrophils present with marks of activation in HIV-infected sub-
jects, including high cell surface expression of the program death ligand
1 PD-L1 (Bowers et al., 2014) and of the adhesionmolecules CD11b and
CD18, as well as low cell surface expression of CD62L (Elbim et al.,
1994), and PD-L1 expression has been shown to remain elevated on
ART (Bowers et al., 2014). Inﬂammation is also evident in HIV patients,
and for instance the routine marker CRP and the soluble form of TNFα
receptor II has been reported to be incompletely reduced under treat-
ment (Brazille et al., 2003; Aukrust et al., 1999; French et al., 2009;
Calmy et al., 2009; Guimaraes et al., 2008; Regidor et al., 2011; Baker
et al., 2011; van Vonderen et al., 2009; Funderburg et al., 2010;
Shikuma et al., 2011). Various soluble markers have been used to mon-
itor the activation of endothelial cells in the course of HIV infection, and
some of them have been reported to be still increased after 12 years of
ART (Rhönsholt et al., 2013). Finally, high levels of the main marker of
ﬁbrinolysis D-dimer have been observed (Kuller et al., 2008; Rodger et
al., 2009; Neuhaus et al., 2010) that are not normalized under cART
(Neuhaus et al., 2010).
Many studies have explored different aspects of this chronic im-
mune, endothelial and coagulation activation, but we still lack a global
picture of this phenomenon. Also, whether all patients have the same
proﬁle of activation or if various proﬁles may be distinguished remains
unknown. This question is of major importance if we want to elucidate
the speciﬁc role played by the different causes of immune activation,
and for instance if some causes will favour some types of immune
activation and other causes other types. It is also of importance if
we want to have a better insight into the links between immune
activation and comorbidities. A global analysis of immune activation
might help us to assess if some proﬁles of immune activation favour
speciﬁcally some morbidities. It is with this aim in mind, that we
carried out an extensive characterization of the immune, endothelial
and coagulation activation in HIV patients aviremic under treatment.
This study enabled us to deﬁne ﬁve different proﬁles of immune
activation in virologic responders.2. Materials and methods
2.1. Study design
We carried out a cross-sectional observational study at two Univer-
sity Hospitals in France (Montpellier and Nîmes). Eligible patients were
HIV-1-infected adults (age N45 years) with pretherapeutic CD4 cell
counts of 350 cells per μL or less, CD4 cell counts of 200 cells per μL or
more in the last 6 months, and plasma viral load below 50 copies per
mL for four time points each separated by 6 months while on a potent,
stable combination antiretroviral regimen. Exclusion criteria were: preg-
nancy, breastfeeding, immunomodulatory therapy, anticancer chemo-
therapy, active hepatitis B or C virus infection, decompensated cirrhosis,
and any non-infectious disease susceptible to impact on the immune
system. The Ethics Committee of the University Hospital of Montpellier
approved this study. All patients provided written informed consent.
2.2. Flow cytometry
Monoclonal antibodies conjugated to ﬂuorescein isothiocyanate
(FITC), phycoerythrin (PE), energy-coupled dye (ECD), PE-Cyanine5.5
(PC5.5), PE-Cyanine7 (PC7), allophycocyanine (APC), APC/Alexa700,
or APC/Alexa750were purchased fromBeckmanCoulter. The antibodies
were used in the following combinations; CD57-FITC/CD279-PE/
CD45RA-ECD/C2-PC5.5/CD27-PC7/CD8-APC/CD4-APC700/CD3-
APC750, CD8-APC/CD4-APC700/CD3-APC750/CD38-PE/HLADR-PC7/
CD20-FITC, CD3-APC750/CD16 APC/HLADR-PC7/CD56-PC5.5/CD69-PE/
CD57-FITC, CD4-FITC/CD45RA-ECD/CD25 PC7/FOXP3-APC/CD127-
APC750. Whole blood collected into EDTA tubes was stained within
1 hour for 10 min at room temperature in the dark with cocktail of an-
tibodies and ﬁxed using IntraPrep Permeabilization Reagent Kit
(Beckman Coulter) according to manufacturer's protocol. Cells were
run on a Navios ﬂow cytometer and results were analyzed by using
Kaluza software (Beckman Coulter). A minimum 20,000 lymphocytes
were gated to analyze the subpopulations. Representative gating strate-
gies and images of ﬂow plots are shown in Supplementary Fig. 1. We
controlled the inter-run variability with the same batch of FlowSet Pro
Beads (Beckman Coulter). The targets were deﬁned on the samples set-
tings (voltages). During the study, no voltage adjustment has been nec-
essary to keep the beads into their respective deﬁned targets.
2.3. Metabolic and soluble immunologic markers in peripheral blood
ELISA was used to quantify soluble TNF receptor I (sTNFRI), sCD14
and sCD163 (Quantikine, R&D systems), as well as tissue Plasminogen
Activator, soluble Thrombomodulin, and soluble Endothelial Protein C
Receptor (Asserachrom, Stago) in plasma collected into EDTA
Vacutainer tubes (Becton Dickinson) and frozen. CRP and immunoglob-
ulins were measured by turbidimetry in serum collected into SST II
Vacutainer tubes, and D-dimers in blood collected into CTADVacutainer
tubes (Becton Dickinson). Blood triglyceride, high-density lipoprotein
(HDL) cholesterol, and insulin levels were quantiﬁed in serum collected
into SST II Vacutainer tubes (Becton Dickinson) after 8 hours of fasting.
2.4. Statistical analysis
WeusedWilcoxon tests to compare patients and donors, and Spear-
man rank correlations to evaluate the link between biomarkers with p-
values multiplicity-adjusted by the False Discovery Rate method. We
sorted the dataset with two independent hierarchical clustering analy-
ses using respectively correlation and Euclidean distance to measure
proximities/distances between markers and patients. The heatmap
was generated using the heatmap function of the software R. The classi-
ﬁcations usedWard (on the squared distance) as a metric. The distance
was the euclidean for the patients and 1-abs (correlation) for markers.
We used ANOVA results corrected by False Discovery Rate for multiple
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different for at least one group of patients with regards to the other
ones. Logistic regressionswere carried out in order to study the relation-
ship between proﬁles of immune activation and metabolic syndrome.
Univariate analyses were ﬁrst performed, and an adjustment by the
age was thereafter executed. To study the relationship between activa-
tionmarkers of various components of the immune, endothelial and co-
agulation systems,we performed spearman correlations, and a Principal
Component Analysis (PCA) after standardization of our variables. PCA
allowed us to analyze multiple correlated values simultaneously, and
to represent it as a set of new orthogonal variables called principal com-
ponents, linear combinations of the variables. Then, the analysis of the
components was carried out in order to highlight the degree of correla-
tion between the variables. Statistical analyses were carried out using
SAS EnterpriseGuide V4.3 (SAS Institute Inc.), and RV3.1.1 (TheR Foun-
dation for Statistical Computing). A p-value lower than 0.05was consid-
ered statistically signiﬁcant.
3. Funding source
University Hospitals of Nîmes and Montpellier. The funding sources
were involved neither in the study design, in the collection, analysis and
interpretation of data, in the writing of the report, nor in the decision to
submit the article for publication.Table 1
Bioclinical and therapeutic characteristics of the study populations. ND, not determined; NA, n
verse transcriptase inhibitor.
Characteristic HIV−
Number of individuals 20
Age Mean (±SD) 54.6 (
Median (min–max) 53.0 (
Male sex N (%) 16 (8
Caucasians N (%) 20 (1
% CD4+ T cell Mean (±SD) ND
Median (min–max) ND
CD4 count (/mm3) Mean (±SD) ND
Median (min–max) ND
CD4:CD8 ratio Mean (±SD) ND
Median (min–max) ND
Pretherapeutic nadir CD4 count
(cells/μL)
Mean (±SD) NA
Median (min–max) NA
Pretherapeutic viremia (RNA copies/ml) Mean (±SD) NA
Median (min–max) NA
Years of HIV infection Mean (±SD) NA
Median (min–max) NA
Duration of viral suppression (months) Mean (±SD) NA
Median (min–max) NA
NRTI N (%) NA
NNRTI N (%) NA
Protease inhibitor N (%) NA
Integrase inhibitor N (%) NA
HBs Ag+ N (%) ND
Anti-HBs Ab+ N (%) ND
Anti-HBc Ab+ N (%) ND
HCV coinfection N (%) ND
CMV coinfection N (%) ND
EBV coinfection N (%) ND
HAV coinfection N (%) ND
Systolic blood pressure (mmHg) Mean (±SD) ND
Median (min–max) ND
Diastolic blood pressure (mmHg) Mean (±SD) ND
Median (min–max) ND
Waist circumference (cm) Mean (±SD) ND
Median (min–max) ND
Lipodystrophy N (%) ND
Insulinemia (μUl/ml) Mean (±SD) ND
Median (min–max) ND
Triglyceridemia (mM/L) Mean (±SD) ND
Median (min–max) ND
HDL serum level (mM/L) Mean (±SD) ND
Median (min–max) ND4. Results
4.1. Study subjects
Between April 29 and September 17, 2014, we recruited 22 female
and 98 male HIV virologic responders (Table 1). Ninety-ﬁve percent of
them were Caucasians. For all patients included, mean CD4 cell count
was 688 (SD 326) cells per μL with a mean CD4:CD8 ratio of 0.99 (SD
0.52). Mean duration of HIV infection was 17.2 (SD 7.4) years with a
mean pretherapeutic CD4 cell count of 192 (SD 108) cells per μL. 29%
were current smokers, and 19% former smokers. The percentages of pa-
tients presenting with hepatitis A virus (HAV), hepatitis B virus (HBV),
hepatitis C virus (HCV), cytomegalovirus (CMV), or Epstein-Barr virus
(EBV) infection were 72%, 42%, 5%, 91%, and 98% respectively. Sex- and
age-matched HIV-uninfected and HIV-infected, viremic, untreated cau-
casians were enrolled as negative and positive controls, respectively.
4.2. Activation markers
We selected markers known to be modiﬁed in untreated HIV pa-
tients, and potentially in treated HIV patients (Younas et al., 2015). At
the T lymphocyte surface, we chose the activation markers HLA-DR
and CD38, as well as the inhibitory receptor Programmed cell Death 1
(PD-1 or CD279). CD45RA and CD27 were used to distinguish naïveot applicable; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside re-
HIV+ treated HIV+ untreated
120 10
±6.4) 56.5 (±8.0) 52.8 (±10.2)
46.0–69.0) 55.0 (45.0–83.0) 50.5 (36.0–68.0)
0) 98 (82) 8 (80)
00) 114 (95) 10 (100)
34.7 (±9.8) 29.6 (±10.7)
34.0 (15.0–62.0) 28.0 (16.0–47.0)
688 (±326) 574 (±283)
593 (243–2044) 509 (166–1153)
0.99 (±0.52) 0.65 (±0.33)
0.90 (0.20–3.30) 0.60 (0.20–1.20)
192 (±108) 515 (±304)
187 (1–458) 442 (130–1153)
393,985 (±1,314,356) 58,833 (±55,700)
104,156 (60–12,000,000) 35,234 (1220–170,318)
17.2 (±7.4) 1.1 (±1.6)
18.0 (3.6–30.4) 0.3 (0.1–4.2)
102 (±47) NA
95 (25–217) NA
108 (90) NA
46 (38) NA
61 (51) NA
34 (28) NA
3 (2) 0 (0)
53 (44) 6 (60)
50 (42) 2 (20)
6 (5) 0 (0)
109 (91) 9 (90)
118 (98) 10 (100)
87 (72) 7 (70)
128 (±16) 124 (±14)
127 (100–181) 128 (100–136)
80 (±11) 82 (±10)
80 (60–120) 82 (60–94)
91 (±11) 89 (±10)
91 (65–128) 85 (82–108)
40 (33) 0 (0)
11 (±7) 7 (±5)
9 (1–45) 7 (2–17)
1.86 (±1.75) 1.55 (±1.59)
1.57 (0.58–17.60) 1.10 (0.64–5.70)
1.45 (±0.61) 1.25 (±0.55)
1.33 (0.16–4.20) 1.17 (0.50–2.42)
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alongwith CD27 and/or CD28 loss were used to characterize T lympho-
cyte senescence. In addition to these markers we also measured CD38
overexpression to evaluate CD8+ T cell activation (Tuaillon et al.,
2009). NK cell activation was monitored analyzing HLA-DR and CD69
expression, NK cell dysfunction CD56 loss, and NK cell senescence
CD57 gain. B cell hyperactivity was assessed by quantifying IgG, IgA,
and IgM in the serum. The plasma level of sCD14 and sCD163 were
used as indicators ofmonocyte/macrophage activation, and that of sTNFRI
and C-reactive protein (CRP) as indicators of inﬂammation. Endothelium
activation was explored by looking for an increase in soluble Endothelial
Protein C Receptor (sEPCR) and in tissue Plasminogen Activator (tPA),
and for a decrease in soluble Thrombomodulin (sThrombomodulin) plas-
ma levels. In a subgroup of patients, D-dimer plasma concentration was
measured aswell as CD64, CD62L, and PD-L1 polynuclear surface density.4.3. Immune activation in virologic responders is global
As compared with HIV-negative controls, we observed in patients
aviremic under cART an increase in the percentages of activated, HLA-
DR+, CD4+ T cells (16 ± 8 and 22 ± 13, p = 0.015), of activated,
HLA-DR+ (45 ± 15, 54 ± 18, p = 0.042), and senescent, CD57+,
CD8+ T cells (18 ± 18, 32 ± 14, p = 0.001), and of activated, HLA-
DR+ (33 ± 22, 52 ± 22, p = 0.002), dysfunctional, CD56- (8 ± 4,Fig. 1. Immune activation in virologic responders. Percentages of various cell populations an
untreated (HIV+ ART–) HIV patients. Data are presented as mean values and 95% conﬁdence i11 ± 7, p = 0.030), and senescent, CD57+ (33 ± 16, 44 ± 18, p =
0.012) NK cells (Fig. 1). Yet, these percentages were lower than those
observed in non-treated HIV-infected individuals. We also observed
an increase in the plasma level of sCD163 (279 ± 158 ng/mL, 467 ±
282 ng/mL, p = 0.033), and sTNFRI (0.9 ± 0.3 ng/mL, 1.2 ± 0.5 ng/
mL, p = 0.012), even though these levels were below those measured
in treatment-naïve patients. CD64 polynuclear surface density was
higher in treated patients than in healthy controls (1.0 ± 0.3 versus
0.8 ± 0.1 arbitrary units, p = 0.030). As compared with virologic re-
sponders (95±56ng/mL) sThrombomodulin concentrationwas higher
in control subjects (142 ± 29 ng/mL, p = 0.008), but lower in viremic
patients. Finally, IgG, IgA, IgM, and D-dimer plasma concentrations in
aviremic patients were lower than in viremic patients, and higher
than in noninfected controls (data not shown). Thus, all the compo-
nents of the innate and adaptative immune system we tested, as well
as the endothelium and the coagulation, appeared globally activated
in the HIV-1-infected individuals we analyzed, even though they had
been aviremic for years.4.4. Links between markers within each component of the immune and en-
dothelial systems
We looked for correlations between the variousmarkerswithin each
cell subpopulation. In CD4+ T cells (Table 2), expression of thed plasma levels of soluble markers in healthy donors (HIV-), treated (HIV+ ART+), and
ntervals; p-values are shown.
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PD-1, and of markers of senescence (CD57 expressionwith andwithout
loss of CD28 and/or CD27). In CD8+ T cells (Table 3), we found no cor-
relation between HLA-DR and CD38 expression. Moreover, in these
lymphocytes, HLA-DR expression, but not that of CD38, was linked to
markers of senescence. Of note, in CD8+ T cells, PD-1 expression was
linked neither to these two markers of activation, nor to markers of se-
nescence. In NK cells (Table 4), the two activation markers HLA-DR and
CD69 were linked together but not to the marker of senescence CD57,
but this latter was linked to the marker of dysfunction CD56-. Of note,
the levels of the monocyte/macrophage activation markers sCD14 and
sCD163 were not linked together (r = 0.087, p = 0.344). By contrast,
the plasma concentrations of IgG and IgA (r = 0.424, p b 0.001), and
IgG and IgM (r= 0.352, p b 0.001) were linked together.
4.5. Correlations between the various markers of the immune, endothelial,
and coagulation activations
As we observed a hyperactivity in all the components we analyzed,
wewonderedwhether the level of activity of someof these components
were linked, either because their activation results from common
causes and/or because they induce each other. To answer this question,
we systematically looked for correlations betweenmarkers characteriz-
ing the activation of the various components of the immune, endothelial
and coagulation systems (Table 5). As characteristic markers, we chose
HLA-DR expression on CD4+ T cells, CD38 overexpression on CD8+ T
cells, CD69 expression on NK cells, CD62L expression on polynuclear
cells, sCD14, IgG, tPA, D-dimer and sTNFRI plasma levels for monocyte,
B cell, endothelial, coagulation activation and inﬂammation, respective-
ly. The only links we uncovered was between HLA-DR expression on
CD4+ T cells and sCD14 level (r = 0.200, p = 0.028) on one hand,
and sTNFRI and D-dimer levels (r = 0.215, p = 0.011) on the other
hand.
In order to comprehensively analyze more globally correlations be-
tween the various activation markers and to obtain a visual representa-
tion, a PCAwas computed, after standardization of the variables (Fig. 2).
We decided to keep two principal components after performing an
elbow test. These two components represented about 35% of the
model's variance (22.70+ 11.96). The results corroborated the conclu-
sions above. For instance, in CD4+T cells, we found a strong correlation
between markers of senescence (CD57 expression with and without
loss of CD28 and/or CD27), and of activation (HLA-DR) and PD-1. By
contrast, D-dimer levels appeared not to be linked to CD4+ T cell and
CD8+ T cell markers.
4.6. Identiﬁcation of different proﬁles of immune activation in patients
aviremic under cART
To test the hypothesis of the existence of different proﬁles of im-
mune activation in patients aviremic under treatment, we sorted the
patients and the 68 markers of lymphocyte, NK cell, monocyte,Table 2
Correlations between CD4+ T cell markers of activation.
% CD4+ T cells
HLA-DR+
% CD4+ T cells
PD-1+
% C
CD5
% CD4+ T cells HLA-DR+ r= 0.393
p b 10−4
r=
p b
% CD4+ T cells PD-1+ r=
p b
% CD4+ T cells CD57+
% CD4+ T cells CD57+CD28–
% CD4+ T cells
CD57+CD28–CD27–endothelium activation and inﬂammation by two independent hierar-
chical clustering analyses (Fig. 3). This clustering outlined the correla-
tions, or the absence thereof, existing between some markers. Some of
these correlations were expected. For instance the correlation between
the percentages of CD8+ T cells positive for HLA-DR and for CD57
shown in Table 3 is illustrated by their proximity in the heatmap (8th
and 10th markers from the right end). This clustering also unveiled
the unexpected absence of links between other markers, such as be-
tween sCD14 and sCD163, as previously mentioned, situated far apart
from each other in the heatmap. It also showed unexpected links be-
tween other markers. For instance, the marker of NK activation HLA-
DR was linked to the marker of endothelium activation tPA (r =
0.261, p=0.004). On the other hand, tPA appeared also linked tomono-
cyte/macrophage activation as estimated by the level of sCD163 (r =
0.244, p= 0.007).
The hierarchical clustering analysis also identiﬁed ﬁve groups of pa-
tients, presentingwith very different proﬁles of immune activation, and
2 outliers (Fig. 3). The levels of more than 80% of the markers were on
average signiﬁcantly different for at least one group of patients with
regards to the other ones. The diversity of the activation proﬁles was ev-
ident when selected activation markers were analyzed (Fig. 4). As com-
paredwith the other groups, group 1 (T8 proﬁle)was characterized by a
high percentage of central memory (CD45RA-CD27+) CD8+ T cells
(31± 13 versus 23± 10%, p=0.0007), group 2 (inﬂammation proﬁle)
by a high level of the inﬂammation marker sTNFRI (1.5 ± 0.3 versus
1.2 ± 0.5 mg/L, p= 0.040), and group 3 (NK proﬁle) by a high number
of activated, CD69+, NK cells (41 ± 43 versus 31 ± 60 cells/μL, p =
0.033). Group 4 (T4 proﬁle) had the highest proportion of CD4+ T
cells expressing CD38 (65 ± 9% versus 55 ± 12%, p b 0.001), and
group 5 (monocyte proﬁle) the highest level of themonocyte activation
marker sCD163 (671±520 ng/mL versus 446±279 ng/mL, p=0.009).
To simplify the identiﬁcation of the ﬁve proﬁles of immune activation,
we looked for a small number of markers able to characterize each pa-
tient group. Using only 8 biomarkers, we were able to classify the pa-
tients in the ﬁve groups with an error rate of 8.5%.
4.7. Relationship between a proﬁle of immune activation and metabolic
syndrome
According to various studies, the frequency of metabolic syndrome
has been reported as 14%–26% (Tebas, 2008) in HIV patients. This syn-
drome is characterized by the presence of at least 3 of the following
components: hypertension, elevated waist circumference or waist-hip
ratio, impaired glucose tolerance, and high triglyceride and/or low
HDL cholesterol (Alberti et al., 2009). As the metabolic syndrome has
been linked to immuneactivation (Esser et al., 2014),we looked for a re-
lationship between this non-AIDS-linked morbidity and the immuno-
logical proﬁles we deﬁned, by carrying out logistic regressions.
Univariate analyses showed that, as compared with the other groups,
patient group 2 presented with higher mean systolic and diastolic
blood pressures, higher waist circumference, and lower HDL cholesterolD4+ T cells
7+
% CD4+ T cells
CD57+CD28–
% CD4+ T cells
CD57+CD28–CD27–
0.585
10−4
r= 0.584
p b 10−4
r= 0.542
p b 10−4
0.375
10−4
r= 0.374
p b 10−4
r= 0.326
p b 10−4
r= 0.998
p b 10−4
r= 0.976
p b 10−4
r= 0.976
p b 10−4
Table 3
Correlations between CD8+ T cell markers of activation.
% CD8+ T cells
HLA-DR+
% CD8+ T
cells CD38+
% CD8+ T
cells CD38hi
% CD8+ T cells
HLA-DR+CD38+
% CD8+ T
cells PD1+
% CD8+ T
cells CD57+
% CD8+ T cells
CD57+CD28–
% CD8+ T cells
CD57+CD28–CD27–
% CD8+ T cells
HLA-DR+
r= 0.615
p b 10−4
r= 0.503
p b 10−4
r= 0.494
p b 10−4
r= 0.462
p b 10−4
% CD8+ Tcells CD38+ r= 0.598
p b 10−4
r= 0.443
p b 10−4
% CD8+ T cells CD38hi r= 0.354
p b 10−4
% CD8+ T cells
HLA-DR+CD38+
r= 0.506
p b 10−4
r= 0.493
p b 10−4
r= 0.436
p b 10−4
% CD8+ T cells PD-1+
% CD8+ T cells CD57+ r= 0.996
p b 10−4
r= 0.905
p b 10−4
% CD8+ T cells
CD57+CD28–
r= 0.907
p b 10−4
% CD8+ T cells
CD57+CD28–CD27–
270 C. Psomas et al. / EBioMedicine 8 (2016) 265–276levels, but these differences did not reach signiﬁcance. The frequency of
hyperinsulinemia (insulinemia N24.9 mIU/L; OR 12.17 [95% CI 1.79–
82.86], p = 0.011, Fig. 5A), and of high (N2.85 mM) triglyceridemia
(OR 4.18 [95% CI 1.08–16.19], p= 0.038, Fig. 5B) was signiﬁcantly ele-
vated in group 2 as comparedwith the other groups. Moreover, the pro-
portion of patients presenting with lipodystrophia was also higher in
group 2 than in the other groups (OR 4.87 [95% CI 1.36–17.39], p =
0.015, Fig. 5C). Thus, the immune activation proﬁle 2 was linked to
major marks of one of non-AIDS comorbidities, the metabolic syn-
drome. Univariate analysis showed that, as compared with the other
groups, patients in group 2 were slightly older (OR 1.08 [95% CI 1.01–
1.16], p=0.023). A multivariate analysis, adjusted with age as a covar-
iate, still highlighted the risk of lipodystrophia (OR 4.37 [95% CI 1.17–
16.33], p= 0.028) and a risk of hyperinsulinemia that was even higher
(OR 17.06 [95% CI 2.14–135.60], p= 0.007) in the group 2.
5. Discussion
In this study, we report a global evaluation of the state of activation
of the immune, endothelial and coagulation systems in 120 treated pa-
tients aviremic for at least 2 years. A ﬁrst conclusion is that these pa-
tients overall present with a generalized hyperactivity of these systems.
A second conclusion is that many markers of the activation of a cell
subpopulation are not equivalent. Analyzing intra-subpopulation corre-
lations, we noticed that HLA-DR expression and CD38 overexpression
on CD8+ T cells were not correlated (Table 3). This is in line with the
fact that these markers may not be coexpressed in vitro (Chadburn et
al., 1992) and in vivo (Espinosa et al., 2013). It is also in agreement
with the initial observation that CD38, but not HLA-DR, is a predictive
marker of the disease progression (Giorgi et al., 1993). Clearly, the ex-
pression of these two markers is largely independent, probably driven
by different mechanisms of activation, and leading to different conse-
quences. Accordingly, CD8+T cell senescence, as indicated by CD57 ap-
pearance and CD27 and/or CD28 loss, correlated with HLA-DR, but notTable 4
Correlations between NK cell markers of activation.
% NK cells HLA-DR+ % NK cells CD69+
% NK cells HLA-DR+ r=−0.501
p b 10−4
% NK cells CD69+
% NK cells HLA-DR+CD69+
% NK cells CD56-
% NK cells CD57+with CD38 expression (Table 3). Strikingly, PD-1 expression was linked
to none of these two activation markers (Table 3). This emphasizes the
notion that the percentage of CD8+ T cells positive for PD-1 is depen-
dent on the stage of differentiation, PD-1 being mostly expressed at an
early and intermediate stage of differentiation, rather than on the
level of activation (Sauce et al., 2007). Indeed, in our study, the percent-
age of CD8+ T cells expressing PD-1 was very strongly (data not
shown) correlated with the percentage of CD8+ T cells CD45RA-
CD27+. Consequently, alternative markers need to be used to measure
exhaustion, as for instance CD160 (Vigano et al., 2014). A striking obser-
vation is also that sCD14 and sCD163 are situated far apart in the bio-
marker clustering. The absence of correlation between these two
monocyte/macrophage activation markers has been reported else-
where (Patro et al., 2016). This is in line with the fact that sCD163, but
not sCD14, has been correlated with HIV load, and may normalize
under antiretroviral therapy (Castley et al., 2014). Likewise, sCD163,
but not sCD14, has been linked to the level of anti-CMV IgG
(Hodowanec et al., 2015) and to liver ﬁbrosis (Mueller et al., 2015). Al-
together these data emphasize the idea that these twomarkers likely do
not reﬂect the same activation pathway.
Another important ﬁnding of our study is that the various pathways
we analyzed are not often activated concurrently. In the individuals we
examined, most of the components of the immune, endothelial and co-
agulation systems, as evaluated by selected markers, appear to be inde-
pendently activated. This raised the interestinghypothesis that virologic
responders might present with different proﬁles of activation.
The ascendant hierarchical classiﬁcation enabled us to cluster activa-
tion markers that ﬂuctuate in the sameway. Apart from some expected
correlations, this classiﬁcation uncovered some unexpected ones. In-
deed, to our knowledge, correlations between NK and endothelium ac-
tivation had never been previously reported in HIV infection. The fact
that activated endothelial cells may release fractalkine, a chemokine
known to activate NK cells (Robinson et al., 2003) might be a mecha-
nism warranting further study. Likewise, no links between monocyte/% NK cells HLA-DR+CD69+ % NK cells CD56- % NK CD57+
r= 0.395
p b 10−4
r= 0.270
p= 0.0029
r=−0.335
p = 0.0479
r= 0.270
p = 0.0002
Table 5
Correlations between markers of immune, endothelial and thrombolysis activation.
% CD4+ T cells
HLA-DR+
% CD8+ T cells
CD38hi
% NK cells
CD69+
CD62L polynuclear cell surface
density
sCD14 IgG sTNFR
I
tPA D-dimer
% CD4+ T cells HLA-DR+ – r= 0.200
p=
0.0284
% CD8+ T cells CD38hi
% NK cells CD69+
CD62L polynuclear cell surface
density
sCD14
IgG
sTNFR I – r= 0.215
p=
0.0107
tPA
D-dimer
271C. Psomas et al. / EBioMedicine 8 (2016) 265–276macrophage and endothelium activation had been described so far in
HIV patients. The fact that tPA has been reported to induce microglial
activation via surface annexin II (Siao and Tsirka, 2002) might account
for the correlation between tPA and sCD163 we uncovered. These ex-
amples highlight the interest of our global approach that may unveilFig. 2. Variables factor map resulting from Principal Component Analysis. The variables are
components to consider. This was done by plotting the components' eigenvalues according
“ﬂat” in order to keep only the components that are placed before the elbow, which were 2 i
with the component. Highly positively correlated variables are represented by arrows clo
diametrically opposed.interactions between the components of the immune, endothelial and
coagulation systems.
Via this global approachwewere able to cluster the patients intoﬁve
different immune activation proﬁles. The diversity of these proﬁles is il-
lustrated by the fact that over 80%of themarkers are variable among therepresented by arrows. The elbow test was carried out in order to select the number of
to their size and analyzing the point in the graph where the slope goes from “steep” to
n our case. The length of each of these arrows depends on the correlation of the variable
se to each other. Strongly negatively correlated variables are represented by arrows
Fig. 3. Virologic responders present with different immune activation proﬁles. Heatmap showing the hierarchical clustering of the activation markers (vertical) as well as of the virologic
responders according to their proﬁle of activation (horizontal). Each group number is indicated.
272 C. Psomas et al. / EBioMedicine 8 (2016) 265–276patient groups. Moreover, each of these groups can be distinguished by
a different immune activation marker. As various factors, including re-
sidual HIV production, microbial translocation, coinfections, metabolic
disorders, CD4+ T cell lymphopenia, immunosenescence, and Treg de-
regulation,may cause immune and endothelial activation, it is tempting
to speculate that these ﬁve proﬁles are the result of different combina-
tions of these etiologic factors. To test this possibility, we are currently
measuring markers speciﬁc for these causes of activation in the same
cohort of patients in order to look for correlations between these differ-
ent causes and the ﬁve proﬁles of activation. To evaluate whether some
coinfectionsmight be coresponsible for the immune activation proﬁle 2,
we looked for a link between markers of these co-infections and this
biomarker proﬁle. As compared with the other patient groups, we did
not ﬁnd any increase in the frequency of either HAV, HBV, HCV or
CMV seropositivity, or EBV load in patient group 2.
It is also possible that each activation proﬁle fuels preferentially
some comorbidities as compared with the other proﬁles. In line with
this hypothesis, we observed a signiﬁcant correlation between one of
the patient group (group 2) and three hallmarks of the metabolic syn-
drome, hypertriglyceridemia, lipodystrophia and hyperinsulinemia. Of
note, a characteristic of patients in group 2 is the high level of sTNFRI,
a marker of TNFα production. Interestingly, TNFα has been reported
to inhibit insulin signalling via thephosphorylation of the Insulin Recep-
tor Substrate 1 (Hotamisligil et al., 1996; Yin et al., 1998; Aguirre et al.,
2000), an effect that favours the development of metabolic syndrome
(Alberti et al., 2009). Moreover, the plasma level of TNFα has beenreported to be correlated with the metabolic syndrome (Shoelson et
al., 2006).
Our study has some limitations. First, the prevalence of sexually
transmitted diseases in patients and the CMV status as well as the pro-
portion of substance abusers in the negative controls were unknown.
These factorsmight confound the comparisons between healthy donors
and HIV adults. It must also be noted that it is a cross-sectional study.
This type of study design enables to showdifferences in immune activa-
tion proﬁles and correlationswith a comorbidity. Yet, a longitudinal fol-
low-up will be needed to test the predicting value of the immune
activation proﬁle of group 2.
From a more general point of view, it will be of interest to look for
correlations between other comorbidities and the immune activation
proﬁles uncovered by the present study. If we establish correlations be-
tween other comorbidities and some immune activation proﬁles, the
simple signature of eight markers we have shown to be able to charac-
terize each proﬁle could be tested for its ability to predict somemorbid-
ities driven by immune/endothelial activation. Of practical interest, the
identiﬁcation of this signature requires a single ﬂow cytometry tube. In
the future, such a signature might enable to tailor prevention and early
diagnosis of non-AIDS-linked morbidities to each patient. Unveiling
links between some causes of immune activation and some immune ac-
tivation proﬁles, and between some immune activation proﬁles and
some comorbidities could also have therapeutic implications.
Uncovering molecular mechanisms responsible for a causative link be-
tween a proﬁle of immune activation and atherothrombosis, liver
Fig. 4. Characterization of the ﬁve different immune activation proﬁles. Differences in the levels of key activationmarkers between each group of patients and the other groups are represented. Data are presented as mean values and 95% conﬁdence
intervals; p-values are shown.
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Fig. 5. Link between immune activation proﬁle 2 and marks of metabolic syndrome. Odd ratios relating each proﬁle of immune activation to risk of hyperinsulinemia (a),
hypertriglyceridemia (b), and lipodystrophy (c). Data are presented as OR and 95% conﬁdence intervals.
274 C. Psomas et al. / EBioMedicine 8 (2016) 265–276steatosis, osteoporosis or neurocognitive impairment could provide us
with new therapeutic targets to prevent and attenuate these chronic
diseases. Moreover, uncovering the causes (HIV and non-HIV infection,
microbial translocation, metabolic dysregulation, CD4+ T cell loss,
immunosenescence, and Treg dysfunction) fueling the immune activa-
tion proﬁle of each patient could open theway to an etiologic treatment.
As these pathogenic pathways are probably not speciﬁc for HIV in-
fection but relevant to any situation of chronic immune activation, in-
cluding aging, and given the frequency of these comorbidities, these
observations are of general interest. It is for instance striking thatHIV in-
fection and the autoimmune disease rheumatoid arthritis share many
common comorbidities, including bone loss, atherosclerosis, metabolic
syndrome, and frailty (Weyand et al., 2014). Thus, our approach could
improve our knowledge on the pathogenic consequences of chronic im-
mune activation, on the pathophysiology of the major chronic diseases
it fuels, aswell as on the prevention of these diseases, their early diagno-
sis and treatment.Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.05.008.
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